

# Robert L Findling

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/6058666/publications.pdf>

Version: 2024-02-01

179  
papers

7,842  
citations

44069

48  
h-index

60623

81  
g-index

203  
all docs

203  
docs citations

203  
times ranked

5027  
citing authors

| #  | ARTICLE  | IF  | CITATIONS |
|----|--|-----|-----------|
| 1  | Developing Empirical Latent Profiles of Impulsive Aggression and Mood in Youths across Three Outpatient Samples. <i>Journal of Clinical Child and Adolescent Psychology</i> , 2023, 52, 196-211.   | 3.4 | 6         |
| 2  | Narrative Review: Impairing Emotional Outbursts: What They Are and What We Should Do About Them. <i>Journal of the American Academy of Child and Adolescent Psychiatry</i> , 2023, 62, 135-150.  | 0.5 | 16        |
| 3  | Safety and effectiveness of lurasidone in adolescents with schizophrenia: results of a 2-year, open-label extension study. <i>CNS Spectrums</i> , 2022, 27, 118-128.   | 1.2 | 11        |
| 4  | Diagnostic Trends and Prescription Patterns in Disruptive Mood Dysregulation Disorder and Bipolar Disorder. <i>Journal of the American Academy of Child and Adolescent Psychiatry</i> , 2022, 61, 434-445.   | 0.5 | 16        |
| 5  | Suicide Risk Screening in Pediatric Outpatient Neurodevelopmental Disabilities Clinics. <i>Journal of Developmental and Behavioral Pediatrics</i> , 2022, 43, 181-187.   | 1.1 | 18        |
| 6  | Vortioxetine for Major Depressive Disorder in Adolescents: 12-Week Randomized, Placebo-Controlled, Fluoxetine-Referenced, Fixed-Dose Study. <i>Journal of the American Academy of Child and Adolescent Psychiatry</i> , 2022, 61, 1106-1118.e2.                  | 0.5 | 8         |
| 7  | Diagnostic accuracy of Achenbach scales in detecting youths'™ substance use disorders.. <i>Psychological Assessment</i> , 2022, 34, 570-582.   | 1.5 | 2         |
| 8  | Physical Activity Levels and Screen Time among Youth with Overweight/Obesity Using Mental Health Services. <i>International Journal of Environmental Research and Public Health</i> , 2022, 19, 2261.  | 2.6 | 5         |
| 9  | Efficacy, Safety, and Tolerability of Flexibly Dosed Ziprasidone in Children and Adolescents with Mania in Bipolar I Disorder: A Randomized Placebo-Controlled Replication Study. <i>Journal of Child and Adolescent Psychopharmacology</i> , 2022, 32, 143-152. | 1.3 | 3         |
| 10 | Efficacy and Safety of Lisdexamfetamine in Preschool Children With Attention-Deficit/Hyperactivity Disorder. <i>Journal of the American Academy of Child and Adolescent Psychiatry</i> , 2022, 61, 1423-1434.  | 0.5 | 6         |
| 11 | Generalizing the Prediction of Bipolar Disorder Onset Across High-Risk Populations. <i>Journal of the American Academy of Child and Adolescent Psychiatry</i> , 2021, 60, 1010-1019.e2.  | 0.5 | 7         |
| 12 | Sleep, Growth, and Puberty After 2 Years of Prolonged-Release Melatonin in Children With Autism Spectrum Disorder. <i>Journal of the American Academy of Child and Adolescent Psychiatry</i> , 2021, 60, 252-261.e3.   | 0.5 | 72        |
| 13 | Predictors of Hospitalization in a Cohort of Children with Elevated Symptoms of Mania. <i>Administration and Policy in Mental Health and Mental Health Services Research</i> , 2021, 48, 171-180.  | 2.1 | 1         |
| 14 | It's™m Not Being Critical, You're™re Just Too Sensitive: Pediatric Bipolar Disorder and Families. <i>Journal of Psychopathology and Behavioral Assessment</i> , 2021, 43, 84-94.   | 1.2 | 2         |
| 15 | Once-Daily SPN-812™200 and 400™mg in the treatment of ADHD in School-aged Children: A Phase III Randomized, Controlled Trial. <i>Clinical Therapeutics</i> , 2021, 43, 684-700.  | 2.5 | 32        |
| 16 | A Phase 3, Placebo-Controlled Trial of Once-Daily Viloxazine Extended-Release Capsules in Adolescents With Attention-Deficit/Hyperactivity Disorder. <i>Journal of Clinical Psychopharmacology</i> , 2021, 41, 370-380.  | 1.4 | 26        |
| 17 | Viloxazine in the Management of CNS Disorders: A Historical Overview and Current Status. <i>CNS Drugs</i> , 2021, 35, 643-653.   | 5.9 | 30        |
| 18 | Diagnosis and Pharmacotherapy of Bipolar Depression in Pediatric Patients. <i>Journal of Clinical Psychiatry</i> , 2021, 82, .   | 2.2 | 0         |

| #  | ARTICLE  | IF  | CITATIONS |
|----|--|-----|-----------|
| 19 | Irritability Is Associated with Illness Severity and Anhedonia Is Associated with Functional Impairment Among Depressed Children and Adolescents. <i>Journal of Child and Adolescent Psychopharmacology</i> , 2021, 31, 531-537.   | 1.3 | 4         |
| 20 | Hopelessness and depressive symptoms in children and adolescents: An integrative data analysis.. <i>Journal of Abnormal Psychology</i> , 2021, 130, 594-607.   | 1.9 | 3         |
| 21 | Management of the COVID-19-Infected Psychiatric Inpatients: Unique Infection Prevention Considerations and Evolving Strategies. <i>Current Treatment Options in Infectious Diseases</i> , 2021, 13, 165-174.   | 1.9 | 2         |
| 22 | Individualizing Treatment Selection for Pediatric and Adult Patients With Bipolar Depression. <i>Journal of Clinical Psychiatry</i> , 2021, 82, .  | 2.2 | 0         |
| 23 | A Phase 3 Placebo-Controlled Trial of Once-Daily 400-mg and 600-mg SPN-812 (Viloxazine) Tj ETQq1 1 0.784314 rgBT /Overlock 10 T5   | 0.0 | 12        |
| 24 | Developing and Validating Short Forms of the Parent General Behavior Inventory Mania and Depression Scales for Rating Youth Mood Symptoms. <i>Journal of Clinical Child and Adolescent Psychology</i> , 2020, 49, 162-177.   | 3.4 | 15        |
| 25 | Associations between Parental Psychopathology and Sexual Behavior in an Outpatient Psychiatric Sample. <i>Journal of Clinical Child and Adolescent Psychology</i> , 2020, 49, 50-59.   | 3.4 | 0         |
| 26 | A Phase II Double-Blind, Placebo-Controlled, Efficacy and Safety Study of SPN-812 (Extended-Release) Tj ETQq0 0 0 rgBT /Overlock 10 T5   | 2.6 | 46        |
| 27 | Developing and Validating a Definition of Impulsive/Reactive Aggression in Youth. <i>Journal of Clinical Child and Adolescent Psychology</i> , 2020, 49, 787-803.  | 3.4 | 8         |
| 28 | Psychopharmacologic Treatment of Schizophrenia in Adolescents and Children. <i>Child and Adolescent Psychiatric Clinics of North America</i> , 2020, 29, 183-210.  | 1.9 | 16        |
| 29 | Development of bipolar disorder and other comorbidity among youth with attentionâ€deficit/hyperactivity disorder. <i>Journal of Child Psychology and Psychiatry and Allied Disciplines</i> , 2020, 61, 175-181.  | 5.2 | 9         |
| 30 | A Phase III, Randomized, Placebo-controlled Trial to Assess the Efficacy and Safety of Once-daily SPN-812 (Viloxazine Extended-release) in the Treatment of Attention-deficit/Hyperactivity Disorder in School-age Children. <i>Clinical Therapeutics</i> , 2020, 42, 1452-1466. | 2.5 | 58        |
| 31 | Affective Processing Biases in Relation to Past, Current, and Future Depression in Children and Adolescents. <i>Journal of Affective Disorders</i> , 2020, 273, 146-156.   | 4.1 | 0         |
| 32 | Evaluating and Validating GBI Mania and Depression Short Forms for Self-Report of Mood Symptoms. <i>Journal of Clinical Child and Adolescent Psychology</i> , 2020, 50, 1-17.  | 3.4 | 7         |
| 33 | Closing the gap: unmet needs of individuals with impulsive aggressive behavior observed in children and adolescents. <i>CNS Spectrums</i> , 2020, 26, 1-9.   | 1.2 | 1         |
| 34 | A Randomized, Double-Blind, Placebo-Controlled Trial of Vilazodone in Children and Adolescents with Major Depressive Disorder with Twenty-Six-Week Open-Label Follow-Up. <i>Journal of Child and Adolescent Psychopharmacology</i> , 2020, 30, 355-365.                          | 1.3 | 11        |
| 35 | Toward prevention of bipolar disorder in at-risk children: Potential strategies ahead of the data. <i>Journal of Affective Disorders</i> , 2020, 272, 508-520.   | 4.1 | 18        |
| 36 | Subtle Motor Signs as a Biomarker for Mindful Movement Intervention in Children with Attention-Deficit/Hyperactivity Disorder. <i>Journal of Developmental and Behavioral Pediatrics</i> , 2020, 41, 349-358.  | 1.1 | 7         |

| #  | ARTICLE   | IF   | CITATIONS |
|----|---|------|-----------|
| 37 | Preliminary evaluation of the utility of parental ratings in a Child Network. <i>Psychiatry Research</i> , 2020, 290, 112908.   | 3.3  | 0         |
| 38 | A novel digital intervention for actively reducing severity of paediatric ADHD (STARS-ADHD): a randomised controlled trial. <i>The Lancet Digital Health</i> , 2020, 2, e168-e178.  | 12.3 | 186       |
| 39 | Development of a Composite Primary Outcome Score for Children with Attention-Deficit/Hyperactivity Disorder and Emotional Dysregulation. <i>Journal of Child and Adolescent Psychopharmacology</i> , 2020, 30, 166-172.   | 1.3  | 10        |
| 40 | Lisdexamfetamine Dimesylate for Preschool Children with Attention-Deficit/Hyperactivity Disorder. <i>Journal of Child and Adolescent Psychopharmacology</i> , 2020, 30, 128-136.  | 1.3  | 8         |
| 41 | Little Agreement on Treating Residual Bipolar Disorder Symptoms in a Child. primary care companion for CNS disorders, <i>The</i> , 2020, 22, .  | 0.6  | 1         |
| 42 | A Novel Assessment Tool for Impulsive Aggression in Children with Attention-Deficit/Hyperactivity Disorder. <i>Journal of Child and Adolescent Psychopharmacology</i> , 2019, 29, 592-598.  | 1.3  | 4         |
| 43 | Factors Influencing Emerging Adultsâ€™ Use of Outpatient Mental Health Services. <i>Evidence-Based Practice in Child and Adolescent Mental Health</i> , 2019, 4, 113-121.   | 1.0  | 3         |
| 44 | Safety considerations in the psychopharmacology of pediatric bipolar disorder. <i>Expert Opinion on Drug Safety</i> , 2019, 18, 777-794.  | 2.4  | 15        |
| 45 | Additional considerations beyond efficacy for lithium in pediatric bipolar disorder. <i>Bipolar Disorders</i> , 2019, 21, 558-559.  | 1.9  | 1         |
| 46 | Maladaptive Aggression: With a Focus on Impulsive Aggression in Children and Adolescents. <i>Journal of Child and Adolescent Psychopharmacology</i> , 2019, 29, 576-591.  | 1.3  | 45        |
| 47 | Application of the Impulsive Aggression Diary in Adolescents with Attention-Deficit/Hyperactivity Disorder. <i>Journal of Child and Adolescent Psychopharmacology</i> , 2019, 29, 599-607.  | 1.3  | 3         |
| 48 | A proposed anti-maladaptive aggression agent classification: improving our approach to treating impulsive aggression. <i>Postgraduate Medicine</i> , 2019, 131, 129-137.  | 2.0  | 8         |
| 49 | Dysregulated Glial Differentiation in Schizophrenia May Be Relieved by Suppression of SMAD4- and REST-Dependent Signaling. <i>Cell Reports</i> , 2019, 27, 3832-3843.e6.  | 6.4  | 32        |
| 50 | Pediatric Prolonged-Release Melatonin for Sleep in Children with Autism Spectrum Disorder: Impact on Child Behavior and Caregiverâ€™s Quality of Life. <i>Journal of Autism and Developmental Disorders</i> , 2019, 49, 3218-3230.                                    | 2.7  | 73        |
| 51 | Adiposity, Hepatic Triglyceride, and Carotid Intima Media Thickness During Behavioral Weight Loss Treatment in Antipsychotic-Treated Youth: A Randomized Pilot Study. <i>Journal of Child and Adolescent Psychopharmacology</i> , 2019, 29, 439-447.                  | 1.3  | 10        |
| 52 | Psychiatric Diseases in Children and Adolescents. <i>Handbook of Experimental Pharmacology</i> , 2019, 261, 397-413.  | 1.8  | 6         |
| 53 | Lithium for the Maintenance Treatment of Bipolar I Disorder: A Double-Blind, Placebo-Controlled Discontinuation Study. <i>Journal of the American Academy of Child and Adolescent Psychiatry</i> , 2019, 58, 287-296.e4.  | 0.5  | 32        |
| 54 | Attendance and Engagement in Parent Training Predict Child Behavioral Outcomes in Children Pharmacologically Treated for Attention-Deficit/Hyperactivity Disorder and Severe Aggression. <i>Journal of Child and Adolescent Psychopharmacology</i> , 2019, 29, 90-99. | 1.3  | 11        |

| #  | ARTICLE  | IF  | CITATIONS |
|----|--|-----|-----------|
| 55 | Clinical, cortical thickness and neural activity predictors of future affective lability in youth at risk for bipolar disorder: initial discovery and independent sample replication. <i>Molecular Psychiatry</i> , 2019, 24, 1856-1867.           | 7.9 | 24        |
| 56 | Diagnostic Accuracy of the CASI-4R Psychosis Subscale for Children Evaluated in Pediatric Outpatient Clinics. <i>Journal of Clinical Child and Adolescent Psychology</i> , 2019, 48, 610-621.  | 3.4 | 2         |
| 57 | Evidence-Based Assessment From Simple Clinical Judgments to Statistical Learning: Evaluating a Range of Options Using Pediatric Bipolar Disorder as a Diagnostic Challenge. <i>Clinical Psychological Science</i> , 2018, 6, 243-265.              | 4.0 | 33        |
| 58 | Decreased functional connectivity in the fronto-parietal network in children with mood disorders compared to children with dyslexia during rest: An fMRI study. <i>NeuroImage: Clinical</i> , 2018, 18, 582-590.                                   | 2.7 | 6         |
| 59 | A Phase 3, Double-Blind, Randomized, Placebo-Controlled Study of Vilazodone in Adolescents with Major Depressive Disorder. <i>Paediatric Drugs</i> , 2018, 20, 353-363.  | 3.1 | 16        |
| 60 | Desvenlafaxine Versus Placebo in the Treatment of Children and Adolescents with Major Depressive Disorder. <i>Journal of Child and Adolescent Psychopharmacology</i> , 2018, 28, 55-65.  | 1.3 | 18        |
| 61 | An update on pharmacotherapy of autism spectrum disorder in children and adolescents. <i>International Review of Psychiatry</i> , 2018, 30, 78-95.   | 2.8 | 103       |
| 62 | The Workforce Shortage of Child and Adolescent Psychiatrists: Is It Time for a Different Approach?. <i>Journal of the American Academy of Child and Adolescent Psychiatry</i> , 2018, 57, 300-301.   | 0.5 | 71        |
| 63 | Diagnostic efficiency of the CBCL thought problems and DSM-oriented psychotic symptoms scales for pediatric psychotic symptoms. <i>European Child and Adolescent Psychiatry</i> , 2018, 27, 1491-1498.   | 4.7 | 19        |
| 64 | Parenting Stress Among Caregivers of Children With Bipolar Spectrum Disorders. <i>Journal of Clinical Child and Adolescent Psychology</i> , 2018, 47, S306-S320.   | 3.4 | 23        |
| 65 | A 6-Month Open-Label Extension Study of Vortioxetine in Pediatric Patients with Depressive or Anxiety Disorders. <i>Journal of Child and Adolescent Psychopharmacology</i> , 2018, 28, 47-54.  | 1.3 | 12        |
| 66 | Asenapine Treatment in Pediatric Patients with Bipolar I Disorder or Schizophrenia: A Review. <i>Paediatric Drugs</i> , 2018, 20, 121-134.   | 3.1 | 9         |
| 67 | Diagnostic Efficiency of the Child and Adolescent Symptom Inventory (CASI-4R) Depression Subscale for Identifying Youth Mood Disorders. <i>Journal of Clinical Child and Adolescent Psychology</i> , 2018, 47, 832-846.                            | 3.4 | 7         |
| 68 | Drs. Stepanova and Findling Reply. <i>Journal of the American Academy of Child and Adolescent Psychiatry</i> , 2018, 57, 978-979.  | 0.5 | 0         |
| 69 | Asenapine pharmacokinetics and tolerability in a pediatric population. <i>Drug Design, Development and Therapy</i> , 2018, Volume 12, 2677-2693.   | 4.3 | 8         |
| 70 | Progress in diagnosis and treatment of bipolar disorder among children and adolescents: an international perspective. <i>Evidence-Based Mental Health</i> , 2018, 21, 177-181.   | 4.5 | 25        |
| 71 | Long-Term Efficacy and Safety of Pediatric Prolonged-Release Melatonin for Insomnia in Children with Autism Spectrum Disorder. <i>Journal of Child and Adolescent Psychopharmacology</i> , 2018, 28, 699-710.                                      | 1.3 | 100       |
| 72 | Post hoc analyses of asenapine treatment in pediatric patients with bipolar I disorder: efficacy related to mixed or manic episode, stage of illness, and body weight. <i>Neuropsychiatric Disease and Treatment</i> , 2018, Volume 14, 1941-1952. | 2.2 | 5         |

| #  | ARTICLE   | IF   | CITATIONS |
|----|---|------|-----------|
| 73 | Comparing the Diagnostic Accuracy of Five Instruments for Detecting Posttraumatic Stress Disorder in Youth. <i>Journal of Clinical Child and Adolescent Psychology</i> , 2017, 46, 511-522.   | 3.4  | 12        |
| 74 | Lithium in Paediatric Patients with Bipolar Disorder: Implications for Selection of Dosage Regimens via Population Pharmacokinetics/Pharmacodynamics. <i>Clinical Pharmacokinetics</i> , 2017, 56, 77-90.   | 3.5  | 36        |
| 75 | Development of Alcohol and Drug Use in Youth With Manic Symptoms. <i>Journal of the American Academy of Child and Adolescent Psychiatry</i> , 2017, 56, 149-156.  | 0.5  | 7         |
| 76 | The Treatment of Severe Childhood Aggression Study: 12 Weeks of Extended, Blinded Treatment in Clinical Responders. <i>Journal of Child and Adolescent Psychopharmacology</i> , 2017, 27, 52-65.  | 1.3  | 21        |
| 77 | Pharmacokinetics and Safety of Vortioxetine in Pediatric Patients. <i>Journal of Child and Adolescent Psychopharmacology</i> , 2017, 27, 526-534.   | 1.3  | 13        |
| 78 | Efficacy and Safety of Pediatric Prolonged-Release Melatonin for Insomnia in Children With Autism Spectrum Disorder. <i>Journal of the American Academy of Child and Adolescent Psychiatry</i> , 2017, 56, 948-957.e4.                                  | 0.5  | 196       |
| 79 | Clinical Implications From the Treatment of Severe Childhood Aggression (TOSCA) Study: A Re-Analysis and Integration of Findings. <i>Journal of the American Academy of Child and Adolescent Psychiatry</i> , 2017, 56, 1026-1033.                      | 0.5  | 13        |
| 80 | The International Society for Bipolar Disorders Task Force report on pediatric bipolar disorder: Knowledge to date and directions for future research. <i>Bipolar Disorders</i> , 2017, 19, 524-543.  | 1.9  | 152       |
| 81 | Human iPSC Glial Mouse Chimeras Reveal Glial Contributions to Schizophrenia. <i>Cell Stem Cell</i> , 2017, 21, 195-208.e6.  | 11.1 | 204       |
| 82 | Reading related white matter structures in adolescents are influenced more by dysregulation of emotion than behavior. <i>NeuroImage: Clinical</i> , 2017, 15, 732-740.  | 2.7  | 3         |
| 83 | A Double-Blind and Placebo-Controlled Trial of Aripiprazole in Symptomatic Youths at Genetic High Risk for Bipolar Disorder. <i>Journal of Child and Adolescent Psychopharmacology</i> , 2017, 27, 864-874.   | 1.3  | 23        |
| 84 | Psychopharmacology of Bipolar Disorders in Children and Adolescents. <i>Pediatric Clinics of North America</i> , 2017, 64, 1209-1222.   | 1.8  | 22        |
| 85 | Positive Emotion Specificity and Mood Symptoms in an Adolescent Outpatient Sample. <i>Cognitive Therapy and Research</i> , 2017, 41, 393-405.   | 1.9  | 9         |
| 86 | Risperidone Added to Psychostimulant in Children with Severe Aggression and Attention-Deficit/Hyperactivity Disorder: Lack of Effect on Attention and Short-Term Memory. <i>Journal of Child and Adolescent Psychopharmacology</i> , 2017, 27, 117-124. | 1.3  | 8         |
| 87 | Comparing the CASI-4R and the PGBI-10ÂM for Differentiating Bipolar Spectrum Disorders from Other Outpatient Diagnoses in Youth. <i>Journal of Abnormal Child Psychology</i> , 2017, 45, 611-623.   | 3.5  | 7         |
| 88 | Using machine learning and surface reconstruction to accurately differentiate different trajectories of mood and energy dysregulation in youth. <i>PLoS ONE</i> , 2017, 12, e0180221.   | 2.5  | 0         |
| 89 | Pharmacotherapy of emotional and behavioral symptoms associated with autism spectrum disorder in children and adolescents. <i>Dialogues in Clinical Neuroscience</i> , 2017, 19, 395-402.   | 3.7  | 39        |
| 90 | Baseline Characteristics and Early Response at Week 1 Predict Treatment Outcome in Adolescents With Bipolar Manic or Mixed Episode Treated With Olanzapine. <i>Journal of Clinical Psychiatry</i> , 2017, 78, e1158-e1166.                              | 2.2  | 6         |

| #   | ARTICLE  | IF   | CITATIONS |
|-----|--|------|-----------|
| 91  | Disruptive Mood Dysregulation Disorder and Bipolar Disorder Not Otherwise Specified: Fraternal or Identical Twins?. <i>Journal of Child and Adolescent Psychopharmacology</i> , 2016, 26, 138-146.   | 1.3  | 25        |
| 92  | Atomoxetine Increased Effect over Time in Adults with Attention-Deficit/Hyperactivity Disorder Treated for up to 6 Months: Pooled Analysis of Two Double-Blind, Placebo-Controlled, Randomized Trials. <i>CNS Neuroscience and Therapeutics</i> , 2016, 22, 546-557.     | 3.9  | 8         |
| 93  | Long-term Safety of Asenapine in Pediatric Patients Diagnosed With Bipolar I Disorder: A 50-Week Open-Label, Flexible-Dose Trial. <i>Paediatric Drugs</i> , 2016, 18, 367-378.   | 3.1  | 22        |
| 94  | Cognitive flexibility and performance in children and adolescents with threshold and sub-threshold bipolar disorder. <i>European Child and Adolescent Psychiatry</i> , 2016, 25, 625-638.  | 4.7  | 24        |
| 95  | Lurasidone for the Treatment of Irritability Associated with Autistic Disorder. <i>Journal of Autism and Developmental Disorders</i> , 2016, 46, 1153-1163.  | 2.7  | 70        |
| 96  | Disruptive Mood Dysregulation Disorder in a Community Mental Health Clinic: Prevalence, Comorbidity and Correlates. <i>Journal of Child and Adolescent Psychopharmacology</i> , 2016, 26, 123-130.   | 1.3  | 62        |
| 97  | Population pharmacokinetics of methylphenidate hydrochloride extended-release multiple-layer beads in pediatric subjects with attention deficit hyperactivity disorder. <i>Drug Design, Development and Therapy</i> , 2015, 9, 2767.                                     | 4.3  | 10        |
| 98  | Pharmacokinetics and Tolerability of Lurasidone in Children and Adolescents With Psychiatric Disorders. <i>Clinical Therapeutics</i> , 2015, 37, 2788-2797.  | 2.5  | 37        |
| 99  | White Matter Structure in Youth With Behavioral and Emotional Dysregulation Disorders. <i>JAMA Psychiatry</i> , 2015, 72, 367.   | 11.0 | 32        |
| 100 | Safety and Efficacy from an 8 Week Double-Blind Trial and a 26 Week Open-Label Extension of Asenapine in Adolescents with Schizophrenia. <i>Journal of Child and Adolescent Psychopharmacology</i> , 2015, 25, 384-396.  | 1.3  | 36        |
| 101 | Asenapine for the Acute Treatment of Pediatric Manic or Mixed Episode of Bipolar I Disorder. <i>Journal of the American Academy of Child and Adolescent Psychiatry</i> , 2015, 54, 1032-1041.  | 0.5  | 50        |
| 102 | Unfiltered Administration of the YMRS and CDRS-R in a Clinical Sample of Children. <i>Journal of Clinical Child and Adolescent Psychology</i> , 2015, 44, 992-1007.  | 3.4  | 15        |
| 103 | Decreased amygdala-insula resting state connectivity in behaviorally and emotionally dysregulated youth. <i>Psychiatry Research - Neuroimaging</i> , 2015, 231, 77-86.   | 1.8  | 61        |
| 104 | Improving Clinical Prediction of Bipolar Spectrum Disorders in Youth. <i>Journal of Clinical Medicine</i> , 2014, 3, 218-232.  | 2.4  | 2         |
| 105 | The safety and effectiveness of open-label extended-release carbamazepine in the treatment of children and adolescents with bipolar I disorder suffering from a manic or mixed episode. <i>Neuropsychiatric Disease and Treatment</i> , 2014, 10, 1589.                  | 2.2  | 26        |
| 106 | Guanfacine Extended Release Adjunctive to a Psychostimulant in the Treatment of Comorbid Oppositional Symptoms in Children and Adolescents with Attention-Deficit/Hyperactivity Disorder. <i>Journal of Child and Adolescent Psychopharmacology</i> , 2014, 24, 245-252. | 1.3  | 28        |
| 107 | Parsing Dimensional vs Diagnostic Category-Related Patterns of Reward Circuitry Function in Behaviorally and Emotionally Dysregulated Youth in the Longitudinal Assessment of Manic Symptoms Study. <i>JAMA Psychiatry</i> , 2014, 71, 71.                               | 11.0 | 45        |
| 108 | Efficacy and Safety of Extended-Release Quetiapine Fumarate in Youth with Bipolar Depression: An 8 Week, Double-Blind, Placebo-Controlled Trial. <i>Journal of Child and Adolescent Psychopharmacology</i> , 2014, 24, 325-335.  | 1.3  | 65        |

| #   | ARTICLE   | IF  | CITATIONS |
|-----|---|-----|-----------|
| 109 | Demographic and clinical correlates of autism symptom domains and autism spectrum diagnosis. <i>Autism</i> , 2014, 18, 571-582.   | 4.1 | 25        |
| 110 | Diagnostic validity and reliability of a Korean version of the Parent and Adolescent General Behavior Inventories. <i>Comprehensive Psychiatry</i> , 2014, 55, 1730-1737.   | 3.1 | 13        |
| 111 | Predictors and moderators of agreement between clinical and research diagnoses for children and adolescents.. <i>Journal of Consulting and Clinical Psychology</i> , 2014, 82, 1151-1162.   | 2.0 | 44        |
| 112 | The 24-month course of manic symptoms in children. <i>Bipolar Disorders</i> , 2013, 15, 669-679.  | 1.9 | 42        |
| 113 | Clinical Significance of Treatment Effects with Aripiprazole versus Placebo in a Study of Manic or Mixed Episodes Associated with Pediatric Bipolar I Disorder. <i>Journal of Child and Adolescent Psychopharmacology</i> , 2013, 23, 72-79.                                  | 1.3 | 24        |
| 114 | Aripiprazole for the treatment of pediatric bipolar I disorder: a 30-week, randomized, placebo-controlled study. <i>Bipolar Disorders</i> , 2013, 15, 138-149.  | 1.9 | 62        |
| 115 | Post-Acute Effectiveness of Lithium in Pediatric Bipolar I Disorder. <i>Journal of Child and Adolescent Psychopharmacology</i> , 2013, 23, 80-90.   | 1.3 | 52        |
| 116 | Efficacy, Long-Term Safety, and Tolerability of Ziprasidone in Children and Adolescents with Bipolar Disorder. <i>Journal of Child and Adolescent Psychopharmacology</i> , 2013, 23, 545-557.   | 1.3 | 48        |
| 117 | Efficacy and Safety of Quetiapine in Adolescents with Schizophrenia Investigated in a 6-Week, Double-Blind, Placebo-Controlled Trial. <i>Journal of Child and Adolescent Psychopharmacology</i> , 2012, 22, 327-342.  | 1.3 | 57        |
| 118 | Examining the Proposed Disruptive Mood Dysregulation Disorder Diagnosis in Children in the Longitudinal Assessment of Manic Symptoms Study. <i>Journal of Clinical Psychiatry</i> , 2012, 73, 1342-1350.  | 2.2 | 147       |
| 119 | Double-Blind, Randomized, Placebo-Controlled Long-Term Maintenance Study of Aripiprazole in Children With Bipolar Disorder. <i>Journal of Clinical Psychiatry</i> , 2012, 73, 57-63.  | 2.2 | 58        |
| 120 | Dosing Strategies for Lithium Monotherapy in Children and Adolescents with Bipolar I Disorder. <i>Journal of Child and Adolescent Psychopharmacology</i> , 2011, 21, 195-205.   | 1.3 | 44        |
| 121 | Efficacy and Safety of Lisdexamfetamine Dimesylate in Adolescents With Attention-Deficit/Hyperactivity Disorder. <i>Journal of the American Academy of Child and Adolescent Psychiatry</i> , 2011, 50, 395-405.   | 0.5 | 101       |
| 122 | Changes in Emotions Related to Medication Used to Treat ADHD. Part II: Clinical Approaches. <i>Journal of Attention Disorders</i> , 2011, 15, 113-121.  | 2.6 | 6         |
| 123 | An Open-Label Study of Aripiprazole in Children with a Bipolar Disorder. <i>Journal of Child and Adolescent Psychopharmacology</i> , 2011, 21, 345-351.   | 1.3 | 20        |
| 124 | First-Dose Pharmacokinetics of Lithium Carbonate in Children and Adolescents. <i>Journal of Clinical Psychopharmacology</i> , 2010, 30, 404-410.  | 1.4 | 32        |
| 125 | Longitudinal Assessment of Manic Symptoms (LAMS) Study. <i>Journal of Clinical Psychiatry</i> , 2010, 71, 1511-1517.  | 2.2 | 75        |
| 126 | A 6-Month, Open-Label, Extension Study of the Tolerability and Effectiveness of the Methylphenidate Transdermal System in Adolescents Diagnosed with Attention-Deficit/Hyperactivity Disorder. <i>Journal of Child and Adolescent Psychopharmacology</i> , 2010, 20, 365-375. | 1.3 | 17        |



| #   | ARTICLE  | IF  | CITATIONS |
|-----|--|-----|-----------|
| 127 | Characteristics of Children With Elevated Symptoms of Mania. <i>Journal of Clinical Psychiatry</i> , 2010, 71, 1664-1672.  | 2.2 | 111       |
| 128 | Effectiveness, Safety, and Tolerability of Lisdexamfetamine Dimesylate in Children With Attention-Deficit/Hyperactivity Disorder: An Open-Label, Dose-Optimization Study. <i>Journal of Child and Adolescent Psychopharmacology</i> , 2009, 19, 649-662.                                 | 1.3 | 41        |
| 129 | Long-term tolerability of the methylphenidate transdermal system in pediatric attention-deficit/hyperactivity disorder: A multicenter, prospective, 12-month, open-label, uncontrolled, phase III extension of four clinical trials. <i>Clinical Therapeutics</i> , 2009, 31, 1844-1855. | 2.5 | 35        |
| 130 | An Open-Label Study of Aripiprazole: Pharmacokinetics, Tolerability, and Effectiveness in Children and Adolescents with Conduct Disorder. <i>Journal of Child and Adolescent Psychopharmacology</i> , 2009, 19, 431-439.   | 1.3 | 42        |
| 131 | Acute Treatment of Pediatric Bipolar I Disorder, Manic or Mixed Episode, With Aripiprazole. <i>Journal of Clinical Psychiatry</i> , 2009, 70, 1441-1451.   | 2.2 | 159       |
| 132 | Diagnosis and Treatment of Bipolar Disorder in Young Patients. <i>Journal of Clinical Psychiatry</i> , 2009, 70, e45.  | 2.2 | 6         |
| 133 | A Multiple-Center, Randomized, Double-Blind, Placebo-Controlled Study of Oral Aripiprazole for Treatment of Adolescents With Schizophrenia. <i>American Journal of Psychiatry</i> , 2008, 165, 1432-1441.  | 7.2 | 226       |
| 134 | Long-Term Effectiveness and Safety of Lisdexamfetamine Dimesylate in School-Aged Children with Attention-Deficit/Hyperactivity Disorder. <i>CNS Spectrums</i> , 2008, 13, 614-620.   | 1.2 | 79        |
| 135 | Tolerability and Pharmacokinetics of Aripiprazole in Children and Adolescents With Psychiatric Disorders. <i>Journal of Clinical Psychopharmacology</i> , 2008, 28, 441-446.   | 1.4 | 56        |
| 136 | A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study of Methylphenidate Transdermal System in Pediatric Patients With Attention-Deficit/Hyperactivity Disorder. <i>Journal of Clinical Psychiatry</i> , 2008, 69, 149-159.   | 2.2 | 84        |
| 137 | Developing a 10-Item Mania Scale From the Parent General Behavior Inventory for Children and Adolescents. <i>Journal of Clinical Psychiatry</i> , 2008, 69, 831-839.   | 2.2 | 142       |
| 138 | Atypical antipsychotic treatment of disruptive behavior disorders in children and adolescents. <i>Journal of Clinical Psychiatry</i> , 2008, 69 Suppl 4, 9-14.   | 2.2 | 21        |
| 139 | Venlafaxine in the Treatment of Children and Adolescents with Attention-Deficit/Hyperactivity Disorder. <i>Journal of Child and Adolescent Psychopharmacology</i> , 2007, 17, 433-445.   | 1.3 | 24        |
| 140 | Efficacy and tolerability of lisdexamfetamine dimesylate (NRP-104) in children with attention-deficit/hyperactivity disorder: A Phase III, multicenter, randomized, double-blind, forced-dose, parallel-group study. <i>Clinical Therapeutics</i> , 2007, 29, 450-463.                   | 2.5 | 387       |
| 141 | A26-Week Open-Label Study of Quetiapine in Children with Conduct Disorder. <i>Journal of Child and Adolescent Psychopharmacology</i> , 2007, 17, 1-9.  | 1.3 | 33        |
| 142 | Venlafaxine ER for the Treatment of Pediatric Subjects With Depression. <i>Journal of the American Academy of Child and Adolescent Psychiatry</i> , 2007, 46, 479-488.   | 0.5 | 112       |
| 143 | Treatment of Early-Onset Schizophrenia Spectrum Disorders (TEOSS): Demographic and Clinical Characteristics. <i>Journal of the American Academy of Child and Adolescent Psychiatry</i> , 2007, 46, 979-988.  | 0.5 | 91        |
| 144 | Methylphenidate in the Treatment of Children and Adolescents With Bipolar Disorder and Attention-Deficit/Hyperactivity Disorder. <i>Journal of the American Academy of Child and Adolescent Psychiatry</i> , 2007, 46, 1445-1453.  | 0.5 | 87        |

| #   | ARTICLE  | IF  | CITATIONS |
|-----|--|-----|-----------|
| 145 | Pharmacotherapy of Aggression in a 9-Year-Old With ADHD. <i>Journal of the American Academy of Child and Adolescent Psychiatry</i> , 2007, 46, 653-658.  | 0.5 | 11        |
| 146 | Practice Parameter for the Assessment and Treatment of Children and Adolescents With Bipolar Disorder. <i>Journal of the American Academy of Child and Adolescent Psychiatry</i> , 2007, 46, 107-125.  | 0.5 | 442       |
| 147 | Is There a Role for Clozapine in the Treatment of Children and Adolescents?. <i>Journal of the American Academy of Child and Adolescent Psychiatry</i> , 2007, 46, 423-428.  | 0.5 | 21        |
| 148 | Treatment of Early-Onset Schizophrenia Spectrum Disorders (TEOSS): Rationale, Design, and Methods. <i>Journal of the American Academy of Child and Adolescent Psychiatry</i> , 2007, 46, 969-978.  | 0.5 | 64        |
| 149 | A Pilot Evaluation of the Safety, Tolerability, Pharmacokinetics, and Effectiveness of Memantine in Pediatric Patients with Attention-Deficit/Hyperactivity Disorder Combined Type. <i>Journal of Child and Adolescent Psychopharmacology</i> , 2007, 17, 19-33. | 1.3 | 61        |
| 150 | Double-Blind, Placebo-Controlled Trial of Divalproex Monotherapy in the Treatment of Symptomatic Youth at High Risk for Developing Bipolar Disorder. <i>Journal of Clinical Psychiatry</i> , 2007, 68, 781-788.  | 2.2 | 104       |
| 151 | Diagnosing and Managing Complicated ADHD. <i>Journal of Clinical Psychiatry</i> , 2007, 68, 1963-1970.   | 2.2 | 1         |
| 152 | The Relevance of Pharmacokinetic Studies in Designing Efficacy Trials in Juvenile Major Depression. <i>Journal of Child and Adolescent Psychopharmacology</i> , 2006, 16, 131-145.   | 1.3 | 60        |
| 153 | Effectiveness, Safety, and Pharmacokinetics of Quetiapine in Aggressive Children With Conduct Disorder. <i>Journal of the American Academy of Child and Adolescent Psychiatry</i> , 2006, 45, 792-800.   | 0.5 | 63        |
| 154 | Combination Lithium and Divalproex Sodium in Pediatric Bipolar Symptom Restabilization. <i>Journal of the American Academy of Child and Adolescent Psychiatry</i> , 2006, 45, 142-148.   | 0.5 | 65        |
| 155 | A Double-Blind, Randomized, Placebo-Controlled Trial of Escitalopram in the Treatment of Pediatric Depression. <i>Journal of the American Academy of Child and Adolescent Psychiatry</i> , 2006, 45, 280-288.  | 0.5 | 174       |
| 156 | Comparison of the clinical efficacy of twice-daily Ritalin® and once-daily Equasym®, XL with placebo in children with Attention Deficit/Hyperactivity Disorder. <i>European Child and Adolescent Psychiatry</i> , 2006, 15, 450-459.                             | 4.7 | 46        |
| 157 | Multiple Dose Pharmacokinetics of Paroxetine in Children and Adolescents with Major Depressive Disorder or Obsessive-Compulsive Disorder. <i>Neuropsychopharmacology</i> , 2006, 31, 1274-1285.  | 5.4 | 43        |
| 158 | Early symptoms of mania and the role of parental risk. <i>Bipolar Disorders</i> , 2005, 7, 623-634.  | 1.9 | 89        |
| 159 | Update on the treatment of bipolar disorder in children and adolescents. <i>European Psychiatry</i> , 2005, 20, 87-91.   | 0.2 | 7         |
| 160 | Double-Blind 18-Month Trial of Lithium Versus Divalproex Maintenance Treatment in Pediatric Bipolar Disorder. <i>Journal of the American Academy of Child and Adolescent Psychiatry</i> , 2005, 44, 409-417.   | 0.5 | 188       |
| 161 | Use of antipsychotics in children and adolescents. <i>Journal of Clinical Psychiatry</i> , 2005, 66 Suppl 7, 29-40.  | 2.2 | 26        |
| 162 | Pharmacologic treatment of behavioral symptoms in autism and pervasive developmental disorders. <i>Journal of Clinical Psychiatry</i> , 2005, 66 Suppl 10, 26-31.  | 2.2 | 14        |

| #   | ARTICLE   | IF  | CITATIONS |
|-----|---|-----|-----------|
| 163 | Evaluation of risks associated with short- and long-term psychostimulant therapy for treatment of ADHD in children. <i>Expert Opinion on Drug Safety</i> , 2004, 3, 93-100.   | 2.4 | 21        |
| 164 | Quetiapine in Nine Youths with Autistic Disorder. <i>Journal of Child and Adolescent Psychopharmacology</i> , 2004, 14, 287-294.  | 1.3 | 91        |
| 165 | A Prospective Study of Stimulant Response in Preschool Children: Insights From ROC Analyses. <i>Journal of the American Academy of Child and Adolescent Psychiatry</i> , 2004, 43, 251-259.   | 0.5 | 49        |
| 166 | Somatic treatment for depressive illnesses in children and adolescents. <i>Psychiatric Clinics of North America</i> , 2004, 27, 113-137.  | 1.3 | 4         |
| 167 | Long-Term, Open-Label Study of Risperidone in Children With Severe Disruptive Behaviors and Below-Average IQ. <i>American Journal of Psychiatry</i> , 2004, 161, 677-684.   | 7.2 | 154       |
| 168 | Atypical antipsychotics in the treatment of children and adolescents. <i>Journal of Clinical Psychiatry</i> , 2004, 65 Suppl 6, 3-4.  | 2.2 | 1         |
| 169 | Atypical antipsychotics in the treatment of children and adolescents: clinical applications. <i>Journal of Clinical Psychiatry</i> , 2004, 65 Suppl 6, 30-44.   | 2.2 | 19        |
| 170 | An Open-Label Pilot Study of St. John's Wort in Juvenile Depression. <i>Journal of the American Academy of Child and Adolescent Psychiatry</i> , 2003, 42, 908-914.   | 0.5 | 50        |
| 171 | Methodological Issues and Controversies in Clinical Trials with Child and Adolescent Patients with Bipolar Disorder: Report of a Consensus Conference. <i>Journal of Child and Adolescent Psychopharmacology</i> , 2003, 13, 13-27. | 1.3 | 76        |
| 172 | Somatic treatment for depressive illnesses in children and adolescents. <i>Child and Adolescent Psychiatric Clinics of North America</i> , 2002, 11, 555-578.   | 1.9 | 18        |
| 173 | Use of quetiapine in children and adolescents. <i>Journal of Clinical Psychiatry</i> , 2002, 63 Suppl 13, 27-31.  | 2.2 | 5         |
| 174 | Discriminative validity of parent report of hypomanic and depressive symptoms on the General Behavior Inventory.. <i>Psychological Assessment</i> , 2001, 13, 267-276.  | 1.5 | 117       |
| 175 | Rapid, continuous cycling and psychiatric co-morbidity in pediatric bipolar I disorder. <i>Bipolar Disorders</i> , 2001, 3, 202-210.  | 1.9 | 281       |
| 176 | Rapid, continuous cycling and psychiatric co-morbidity in pediatric bipolar I disorder. <i>Bipolar Disorders</i> , 2001, 3, 202.  | 1.9 | 1         |
| 177 | Paediatric uses of atypical antipsychotics. <i>Expert Opinion on Pharmacotherapy</i> , 2000, 1, 935-945.  | 1.8 | 34        |
| 178 | Pharmacological Treatment of Depression in Children and Adolescents. <i>Paediatric Drugs</i> , 1999, 1, 161-182.  | 3.1 | 41        |
| 179 | Hemoglobin and the brain: a piece of the autism puzzle?. <i>Journal of Autism and Developmental Disorders</i> , 1998, 28, 579-582.  | 2.7 | 2         |